Citigroup set a $132.00 target price on AveXis (NASDAQ:AVXS) in a report published on Friday, January 5th. The firm currently has a buy rating on the stock.
Several other equities research analysts have also issued reports on the stock. Canaccord Genuity set a $110.00 price target on shares of AveXis and gave the company a hold rating in a research note on Wednesday, December 20th. BidaskClub raised shares of AveXis from a sell rating to a hold rating in a research report on Thursday, December 21st. ValuEngine downgraded shares of AveXis from a hold rating to a sell rating in a research report on Friday, December 1st. Bank of America decreased their price objective on shares of AveXis from $115.00 to $112.00 and set a buy rating for the company in a research report on Friday, November 10th. Finally, Royal Bank of Canada lifted their price objective on shares of AveXis from $92.00 to $97.00 and gave the company a sector perform rating in a research report on Friday, November 10th. Three analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have issued a buy rating to the company. AveXis currently has a consensus rating of Buy and an average target price of $111.67.
Shares of AveXis (NASDAQ:AVXS) opened at $116.34 on Friday. AveXis has a 52 week low of $50.56 and a 52 week high of $116.74. The stock has a market cap of $3,720.00 and a price-to-earnings ratio of -20.85.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same quarter in the previous year, the business posted ($0.87) EPS. equities research analysts expect that AveXis will post -6.23 EPS for the current year.
In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $101.23, for a total value of $1,518,450.00. Following the completion of the sale, the insider now owns 1,841,019 shares of the company’s stock, valued at approximately $186,366,353.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $109.72, for a total transaction of $195,301.60. Following the completion of the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $195,301.60. The disclosure for this sale can be found here. Insiders sold a total of 52,340 shares of company stock valued at $5,318,845 in the last three months. Insiders own 18.60% of the company’s stock.
Several large investors have recently modified their holdings of AVXS. Janus Henderson Group PLC acquired a new position in shares of AveXis in the 2nd quarter valued at approximately $55,439,000. BlackRock Inc. raised its position in shares of AveXis by 34.7% in the 2nd quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after buying an additional 592,843 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of AveXis by 4,448.8% in the 2nd quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock valued at $46,418,000 after buying an additional 552,546 shares in the last quarter. FMR LLC raised its position in shares of AveXis by 13.1% in the 2nd quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after buying an additional 544,475 shares in the last quarter. Finally, State Street Corp raised its position in shares of AveXis by 104.2% in the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after buying an additional 510,189 shares in the last quarter. Institutional investors own 92.88% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “AveXis (AVXS) Given a $132.00 Price Target by Citigroup Analysts” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/12/avexis-avxs-given-a-132-00-price-target-by-citigroup-analysts.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.